Usana Health Sciences stock plunged 30% this week after Q2 results missed analyst estimates and company issued disappointing guidance
The company reported adjusted earnings of $0.07 per share on sales of approximately $223 million for the second quarter, falling $0.50 below analyst EPS estimates and $12 million short on revenue. Usana also announced a $29 million goodwill impairment charge on its Hiya business, leading to a revised full-year forecast of an $11 million loss, down from previous guidance of $20 million to $27 million profit. Full-year sales guidance was also lowered from $925 million-$1 billion to $910 million.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Prediction Market Trading Platforms: An Overview of Four Core Platforms
-
2
Bitcoin Hash Rate Plunge: Causes and Impact Analysis
-
3
MELD Token Analysis: Trading Status of DeFi Banking Protocol MELD and the Homonymous MetaElfLand Token
-
4
What Are Bitcoin Futures? A Comprehensive Guide to Their Mechanics and Trading Advantages
-
5
FAC Coin: An Analysis of Flying Avocado Cat's Total Supply and Market Performance
-
6
BLIZZ Token Analysis: Distinguishing Multiple Projects and Current Market Status
-
7
USDC Stablecoin: Issuer, Mechanism, and Market Position Analysis
-
8
KStarCoin (KSC) Value Analysis: Current Status and Investment Considerations for a K-Pop Concept Token
-
9
Polkadot (DOT) In-Depth Analysis: Architecture, Advantages, and Latest Developments
-
10
RPL Token: Current Status, Upgrades, and Investment Outlook for Rocket Pool
Markets Today
Recommended Reading












